Answers are grounded in this paper and cite their sources.
In recent years, poly(ADP-ribose) glycohydrolase (PARG), a key enzyme in DNA damage repair pathways, has emerged as a major focus in anticancer drug discovery. PARG inhibitors exhibit broad-spectrum antitumor effects across diverse tumor types via multiple mechanisms, such as triggering sustained nuclear replication stress and mitotic catastrophe, as well as modulating the stability of cell cycle checkpoint proteins. This review systematically summarizes the mechanisms of action of PARG inhibitors, recent advances in their structural optimization, and their applications in combination with immunotherapy, ATR/CHK1 inhibitors, and natural products, aiming to highlight the unique value and clinical translation prospects of PARG inhibitors as a new generation of highly selective, multi-mechanism antitumor agents.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: